biotech
biotech Articles
Spring Bank Pharmaceuticals has amended it filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
This clinical-stage biopharmaceutical company focused on complex biosimilar therapeutics has filed for an IPO.
Published:
Last Updated:
Baxalta is scheduled to report fourth-quarter and full-year results before markets open on Tuesday.
Published:
Last Updated:
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
Published:
Last Updated:
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Published:
Last Updated:
Clovis Oncology traded down on Friday after the company said the FDA scheduled the New Drug Application for rociletinib for discussion by the Oncologic Drugs Advisory Committee on April 12.
Published:
Last Updated:
Hutchinson China MediTech has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Incyte reported better-than-expectged fourth-quarter financial results after the markets closed on Wednesday.
Published:
Last Updated:
Syndax Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
CTI BioPharma has practically become a penny stock overnight following an update from its Investigational New Drug (IND) application for pacritinib.
Published:
Last Updated:
Proteostasis Therapeutics expects to price less than 4 million shares in the range of $12 to $14 apiece in an initial public offering valued up to around $62 million.
Published:
Last Updated:
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Published:
Last Updated:
Adaptimmune Therapeutics has announced that the FDA granted a Breakthrough Therapy designation for the company's affinity enhanced T-cell therapy.
Published:
Last Updated:
BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
Published:
Last Updated:
After Gilead Sciences reported fourth-quarter financial results on Tuesday, analysts weighed in on this biotech giant and in what direction it might go next.
Published:
Last Updated: